OverviewSuggest Edit

OpGen is uniquely positioned to address the rising antibiotic resistance crisis and is harnessing the power of informatics and genomic analysis to provide complete solutions to protect patients in hospitals and healthcare networks. Using its large and ever-growing Acuitas Lighthouse® Database of pathogens from around the world, the Company is developing disruptive technologies aimed to shift the paradigm for managing infectious diseases.

Through its CLIA-certified clinical laboratory services, OpGen provides rapid detection and analysis of antibiotic resistance and high-resolution microbial sequence analysis. The Company's FDA-cleared, IVD products rapidly identify pathogens in positive blood cultures.

TypePublic
Founded2002
HQGaithersburg, MD, US
Websiteopgen.com
Employee Ratings3

Latest Updates

Employees (est.) (Dec 2018)44(+26%)
Revenue (FY, 2020)$4.2 M(+21%)
Share Price (May 2022)$0.3(-3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at OpGen

Timothy Dec

Timothy Dec

Chief Financial Officer
Vadim Sapiro

Vadim Sapiro

Chief Information Officer
Johannes Bacher

Johannes Bacher

Chief Operating Officer
Faranak Atrzadeh

Faranak Atrzadeh

Chief Marketing and Scientific Affairs Officer
Derek Joesting

Derek Joesting

Senior Vice President, US Sales
Arne Materna

Arne Materna

Managing Director & CEO: Ares Genetics
Show more

OpGen Office Locations

OpGen has offices in Gaithersburg, Rockville, Wien and Holzgerlingen
Gaithersburg, MD, US (HQ)
708 Quince Orchard Rd
Rockville, MD, US
9717 Key W Ave #100
Wien, AT
Karl-Farkas-Gasse 18
Holzgerlingen, DE
Max-Eyth-Straße 42
Show all (4)

OpGen Financials and Metrics

OpGen Revenue

OpGen's revenue was reported to be $4.21 m in FY, 2020
USD

Revenue (Q1, 2021)

829.7k

Net income (Q1, 2021)

(14.9m)

EBIT (Q1, 2021)

(6.3m)

Market capitalization (13-May-2022)

13.5m

Closing stock price (13-May-2022)

0.3

Cash (31-Mar-2021)

39.4m

EV

(2.6m)
OpGen's current market capitalization is $13.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.2m4.0m3.2m2.9m3.5m4.2m

Cost of goods sold

1.2m1.7m1.6m

Gross profit

2.0m2.4m1.6m

Gross profit Margin, %

63%59%50%
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

472.2k375.1k980.8k1.1m1.2m759.7k771.8k703.2k745.1k846.2k788.9k552.2k1.0m1.0m648.2k616.9k1.2m829.7k

Cost of goods sold

115.4k48.2k562.7k346.0k337.0k400.0k425.0k392.8k448.4k342.8k

Gross profit

356.8k326.9k418.1k730.7k845.8k359.7k346.8k310.4k296.7k503.4k

Gross profit Margin, %

76%87%43%68%72%47%45%44%40%59%
USDQ1, 2015

Financial Leverage

-0.3 x
Show all financial metrics

OpGen Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

OpGen Online and Social Media Presence

Embed Graph

OpGen News and Updates

OpGen Reports First Quarter 2022 Financial Results and Provides Business Update

ROCKVILLE, Md., May 12, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2022 financial and operating results. M…

OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

ROCKVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that, following the successful completion of a re…

OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

ROCKVILLE, Md., March 29, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2021 and full-year 2021 financ…

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2021 financial results after the close of the U.S. financial markets on Tuesday, Marc…

OpGen Announces Successful Completion of Unyvero A30 Development Milestone

ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary Curetis has successfully met a key milestone in t…

OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today it is participating in Edison Group’s Open House Event, scheduled to …
Show more

OpGen Blogs

OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time

OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time Content Import Thu, 04/28/2022 - 07:30 OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time …

OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally

OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally Content Import Wed, 04/20/2022 - 07:30 OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally 04.20.22 General …

OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

Publication demonstrates FDA cleared Acuitas AMR Gene Panel detects and differentiates a broad range of 28 AMR markers that can be associated with up to 9 antimicrobial classes Provides results at least a day earlier than traditional methods to guide patient management and support antibiotic

OpGen Announces Results of Special Meeting of Stockholders

OpGen Announces Results of Special Meeting of Stockholders Content Import Wed, 12/08/2021 - 16:33 OpGen Announces Results of Special Meeting of Stockholders 12.08.21 This release is a backfill from a News Wire Earnings ROCKVILLE, Md.…

OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update

Total Revenue for Q3 2021 was approximately $1.2 million Cash as of September 30, 2021 , was approximately $25.4 million , up significantly from the $13.4 million at year-end 2020 Cash balance was further strengthened significantly by $15 million financing completed in October Conference call to be

OpGen Announces Closing of $15 Million Registered Direct Offering

ROCKVILLE, Md. , Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced
Show more

OpGen Frequently Asked Questions

  • When was OpGen founded?

    OpGen was founded in 2002.

  • Who are OpGen key executives?

    OpGen's key executives are Timothy Dec, Vadim Sapiro and Johannes Bacher.

  • How many employees does OpGen have?

    OpGen has 44 employees.

  • What is OpGen revenue?

    Latest OpGen annual revenue is $4.2 m.

  • What is OpGen revenue per employee?

    Latest OpGen revenue per employee is $95.8 k.

  • Who are OpGen competitors?

    Competitors of OpGen include DiaSorin, Xenon Pharmaceuticals and Blue Health Intelligence.

  • Where is OpGen headquarters?

    OpGen headquarters is located at 708 Quince Orchard Rd, Gaithersburg.

  • Where are OpGen offices?

    OpGen has offices in Gaithersburg, Rockville, Wien and Holzgerlingen.

  • How many offices does OpGen have?

    OpGen has 4 offices.